Q2 2026 saw 18% revenue growth and 36% EPS growth, both above guidance, with strong performance in Semi-Cap, AC&C, and Medical. The 2026 revenue outlook was raised to $3 billion, and operational execution improved margins and cash flow. Supply chain tightness remains a risk.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.